DermTech, Inc.

DermTech, Inc., trading under the ticker CNAC, filed an 8-K with the Securities and Exchange Commission on May 27, 2021, reflecting continued corporate activity in the post-combination period following its SPAC transaction. DermTech operates in the precision dermatology and healthcare sector, developing non-invasive genomic testing technology for the early detection of melanoma and other skin cancers. The company completed its business combination with a blank-check acquisition vehicle and subsequently began operating as a publicly traded entity in the healthcare diagnostics space. The May 2021 8-K represents one of several material disclosures filed during the company's integration period. Sign up for full data, filings history, and deal analytics on SpacDesk.